I love that you share your thoughts and a bit of your personal life with us Dr Mandrola( and associates). It is reassuring to have a trusted, educated person sift thru the medical jungle and pull out what is true and important. Thankyou so much.
Thank you John. I love your style of writing. I am so disappointed that Sensible Medicine has turned out to be the Vinay Prasad show. He has a very different style.
Glad to see the biking Dr. M - am 86, have persistent A-fib diagnosed 10 yrs ago. (exhorted to "speed up thru the finish line"). Declined blood thinners, mtn bike every day in hills (live at 750'), refuse to give in to all hype - but yours. All best, Tom
Thank you for your thoughts, Dr. Mandrola, from a general cardiology colleague in western Canada. The PCI comments were very interesting, to say the least. The SGLT2 inhibitors should be used judiciously in those who would derive the greatest benefit, which admittedly involves a fair bit of clinical judgement.
Anyhow, based on EMPEROR-PRESERVED, what do you think of the 2022 ACC HF statement that “In patients with HFpEF, SGLT2i can be beneficial in decreasing HF hospitalizations and cardiovascular MORTALITY.”
Is it right for them to use ‘mortality’ there? As the composite PEP is driven by HHF. Thank you 🫀- Ben, cardiologist, Malaysia
I love that you share your thoughts and a bit of your personal life with us Dr Mandrola( and associates). It is reassuring to have a trusted, educated person sift thru the medical jungle and pull out what is true and important. Thankyou so much.
Thank you John. I love your style of writing. I am so disappointed that Sensible Medicine has turned out to be the Vinay Prasad show. He has a very different style.
Wow, you really look fit! Thanks for the piece - very readable, very informative.
Glad to see the biking Dr. M - am 86, have persistent A-fib diagnosed 10 yrs ago. (exhorted to "speed up thru the finish line"). Declined blood thinners, mtn bike every day in hills (live at 750'), refuse to give in to all hype - but yours. All best, Tom
Thank you for your thoughts, Dr. Mandrola, from a general cardiology colleague in western Canada. The PCI comments were very interesting, to say the least. The SGLT2 inhibitors should be used judiciously in those who would derive the greatest benefit, which admittedly involves a fair bit of clinical judgement.
Interesting take on DELIVER,
Anyhow, based on EMPEROR-PRESERVED, what do you think of the 2022 ACC HF statement that “In patients with HFpEF, SGLT2i can be beneficial in decreasing HF hospitalizations and cardiovascular MORTALITY.”
Is it right for them to use ‘mortality’ there? As the composite PEP is driven by HHF. Thank you 🫀- Ben, cardiologist, Malaysia